Similarly, measuring ERK activity in patient-derived organoids (PDO) of colorectal cancer (CRC) patients showed that both mutant BRAF, mutant NRAS and mutant KRAS PDOs require EGFR stimulation to proliferate [124]. This evidence concerns the gene EGFR and colorectal carcinoma.